Screener
BioMarin Pharmaceuticals BMRN Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $874,005 | $1,311,679 |
| Short-term investments | — | 248,930 |
| Accounts receivable, net | 1,061,047 | 908,214 |
| Inventory | 1,782,524 | 1,298,883 |
| Other current assets | 254,047 | 185,784 |
| Total current assets | 3,971,623 | 3,953,490 |
| Noncurrent assets: |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's accounts receivable?
- BioMarin Pharmaceuticals (BMRN) reported accounts receivable of $1.06B in Q2 2026.
- How has BioMarin Pharmaceuticals's accounts receivable changed year-over-year?
- BioMarin Pharmaceuticals's accounts receivable increased by 24.0% year-over-year, from $855.86M to $1.06B.
- What is the long-term trend for BioMarin Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accounts receivable has grown at a 15.2% compound annual growth rate (CAGR), from $448.35M to $908.21M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about BioMarin Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude